X4 Pharmaceuticals Inc (XFOR) concluded trading on Thursday at a closing price of $0.81, with 7.73 million shares of worth about $6.26 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 20.24% during that period and on December 26, 2024 the price saw a gain of about 38.91%. Currently the company’s common shares owned by public are about 168.51M shares, out of which, 117.85M shares are available for trading.
Stock saw a price change of 25.67% in past 5 days and over the past one month there was a price change of 140.08%. Year-to-date (YTD), XFOR shares are showing a performance of -3.91% which decreased to -4.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.26 but also hit the highest price of $1.60 during that period. The average intraday trading volume for X4 Pharmaceuticals Inc shares is 3.18 million. The stock is currently trading 44.74% above its 20-day simple moving average (SMA20), while that difference is up 58.52% for SMA50 and it goes to 1.45% higher than SMA200.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) currently have 168.51M outstanding shares and institutions hold larger chunk of about 35.58% of that.
The stock has a current market capitalization of $137.41M and its 3Y-monthly beta is at 0.31. It has posted earnings per share of -$0.09 in the same period. It has Quick Ratio of 4.80 while making debt-to-equity ratio of 1.31. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XFOR, volatility over the week remained 20.75% while standing at 20.53% over the month.
Stock’s fiscal year EPS is expected to rise by 77.49% while it is estimated to decrease by -309.09% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on December 12, 2023 offering a Neutral rating for the stock and assigned a target price range of between $3 and $1 to it. Coverage by B. Riley Securities stated X4 Pharmaceuticals Inc (XFOR) stock as a Buy in their note to investors on August 30, 2023, suggesting a price target of $3 for the stock. On December 22, 2022, Cantor Fitzgerald Initiated their recommendations, while on December 12, 2022, Piper Sandler Initiated their ratings for the stock with a price target of $3. Stock get an Outperform rating from Oppenheimer on December 23, 2019.
